Esomeprazole Magnesium Capsules Recalled for Out-of-Specification Potency
Sun Pharmaceutical is recalling Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg nationwide due to superpotency findings. Lot AC14299 (expiration 12/2022) tested out of specification for drug assay at the 12-month stability timepoint.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA classified this recall as Class III, which indicates the product is not likely to cause adverse health consequences. No illnesses or injuries have been reported. The issue is a pharmaceutical quality defect identified through stability testing rather than through patient harm.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg (NDC 63304-734 and 63304-735) distributed nationwide in the United States. The recall affects lot AC14299 with an expiration date of December 2022.
The product was found to be out of specification for drug assay during stability testing conducted at the 12-month timepoint. Specifically, the recalled capsules tested as superpotent, meaning the actual concentration of the active ingredient exceeded the amount specified in the product's approved formulation.
Approximately 5,712 bottles of the recalled lot were distributed nationwide. The product was manufactured by Ohm Laboratories Inc., New Brunswick, NJ, and distributed by Sun Pharmaceutical Industries Inc., Cranbury, NJ. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- ESOMEPRAZOLE MAGNESIUM (ESOMEPRAZOLE MAGNESIUM)
- Brand
- ESOMEPRAZOLE MAGNESIUM
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Affected units
- 5,712
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot AC14299
- Exp 12/2022
UPCs (3)
- 0363304734300
- 0363304734904
- 0363304735307
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by SUN PHARMACEUTICAL INDUSTRIES INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · ESOMEPRAZOLE MAGNESIUM
- ModerateEsomeprazole Magnesium oral suspension recalled for failed impurity specifications
FDA (Drugs) · 2025-05-28
- SevereEsomeprazole Magnesium Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-05-28
- ModeratePrescription drug esomeprazole magnesium recalled for labeling error
FDA (Drugs) · 2024-12-11
- ModeratePrescription esomeprazole magnesium capsules recalled for failed impurity specifications
FDA (Drugs) · 2023-11-29
- ModeratePrescription Drug Esomeprazole Out of Specification for Potency
FDA (Drugs) · 2022-10-05
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · potency deviation
See all →- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium 100 mcg Tablets Recalled for Potency Deviations Nationwide
FDA (Drugs) · 2024-12-18
- HighCloderm Cream Recalled for Manufacturer Quality Assurance Program Discontinuation
FDA (Drugs) · 2024-05-01
- SevereTegsedi Injection Recalled for Higher-Than-Labeled Content
FDA (Drugs) · 2022-07-06